Gilead Sciences News - June 26, 2026

GILD

🟢 GILD is trading 3.1% up today after FDA approves Trodelvy for first-line breast cancer treatment

GILD is trading 3.1% up at $127.69 after the FDA approved its cancer drug Trodelvy for the first-line treatment of metastatic triple-negative breast cancer. •...
Gilead’s Trodelvy Wins FDA Approval for First-Line Breast Cancer, Expanding Market
GILD

Gilead’s Trodelvy Wins FDA Approval for First-Line Breast Cancer, Expanding Market

Gilead Sciences received FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). This approval transitions...